Summary
Orphenadrine has been used as an antiparkinsonian, antispastic and analgesic drug for many years. Here we show that orphenadrine inhibits [3H]MK-801 binding to the phencyclidine (PCP) binding site of the N-methyl-D-aspartate (NMDA)-receptor in homogenates of postmortem human frontal cortex with a Ki-value of 6.0 ± 0.7 μM. The NMDA receptor antagonistic effects of orphenadrine were assessed using concentration- and patch-clamp techniques on cultured superior colliculus neurones. Orphenadrine blocked open NMDA receptor channels with fast kinetics and in a strongly voltage-dependent manner. The IC50-value against steady state currents at −70mV was 16.2 ± 1.6 μM (n=6). Orphenadrine exhibited relatively fast, concentration-dependent open channel blocking kinetics (Kon 0.013 ± 0.002 106M−1S−1) whereas the offset rate was concentration-independent (Koff 0.230 ± 0.004 S−1). Calculation of the ratio Koff/Kon revealed an apparent Kd-value of 17.2 μM which is nearly identical to the IC50 calculated at equilibrium.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Altamura AC, Buccio M, Colacurcio F, Colombo G, Terzi A (1986a) Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta Neurol Napoli 8: 19–26
Altamura AC, Buccio M, Colombo G, Terzi A, Cazzullo CL (1986b) Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study. Encephale 12: 31–36
Bassi S, Albizzati MG, Calloni E, Sbacchi M, Frattola L (1986) Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa. Br J Clin Pract 40: 273–275
Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272–276
Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427–4436
Contin M, Riva R, Albani F, Baruzzi A (1987) Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomed Chromatogr 2: 193–194
Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994) Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? — Case of amantadine and memantine. J Neural Transm [PD Sect] 7: 155–166
Danysz W, Parsons CG, Bresink I, Quack G (1995) Glutamate in CNS disorders. A revived target for drug development? Drug News Perspectives 8: 261–277
Hunskaar S, Donnell D (1991) Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res 19: 71–87
Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ (1994) The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur J Pharmacol 264: 207–211
Klockgether T, Turski L (1993) Towards understanding of the role of glutamate in experimental Parkinsonism: agonist sensitive sites in the basal ganglia. Ann Neurol 34: 585–593
Klockgether T, Jacobson P, Löschmann P-A, Turski L (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm [PD Sect] 5: 101–106
Kornhuber J, Weller M (1995) Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In: Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH (eds) Schizophrenia — an integrated view. Alfred Benzon Symposium 38. Munksgaard, Copenhagen, pp 314–325
Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297–300
Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91–104
Kornhuber J, Herr B, Thome J, Riederer P (1995) The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm [Suppl] 46: 127–133
Labout JJ, Thijssen CT, Keijser GG, Hespe W (1982) Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol 21: 343–350
Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263: 717–724
McPherson GA (1983) A practical computer-based approach to the analysis of radioligand binding experiments. Comput Progr Biomed 17: 107–114
Mindham RHS, Gaind R, Anstee BH, Rimmer L (1972) Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism. Psychol Med 2: 406–413
Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 256: 1217–1221
Munson PJ, Rodbard D (1980) LIGAND: a versatile computerized approach for the characterization of ligand-binding systems. Anal Biochem 107: 220–239
Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetic and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337–1350
Parsons CG, Panchenko VA, Pinchenko UO, Tsyndrenko AY, Krishtal OA (1995a) Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurones on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci (in press)
Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995b) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239–1258
Porter RHP, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64: 614–623
Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung/Drug Res 42: 265–268
Rohrbacher J, Bijak M, Misgeld U (1994) Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices. Neurosci Lett 182: 95–98
Schmidt WJ, Bubser M, Hauber W (1992) Behavioural pharmacology of glutamate in the basal ganglia. J Neural Transm [Suppl] 38: 65–89
Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213: 439–443
Syvälahti EK, Kunelius R, Lauren L (1988) Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol 62: 90–94
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kornhuber, J., Parsons, C.G., Hartmann, S. et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural Transmission 102, 237–246 (1995). https://doi.org/10.1007/BF01281158
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01281158